Beranda › Infeksi Virus › Distrik Columbia › Washington
Uji klinis Infeksi Virus di Washington, DC
12 studi untuk Infeksi Virus mencari peserta di lokasi sekitar Washington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Menerima pesertaFase 3
- Research Site, Washington D.C.
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Menerima pesertaStudi observasional
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Menerima pesertaStudi observasional
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
Menerima pesertaFase 1Sukarelawan sehat diterima
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Menerima pesertaFase 3
- Georgetown University Medical Center, Washington D.C.
- Jadestone Clinical Research, Silver Spring · 7 mi jauhnya
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Menerima pesertaFase 3
- Georgetown University Medical Center, Washington D.C.
- Emerson Clinical Research Institute, Washington D.C.
- Jadestone Clinical Research, Silver Spring · 7 mi jauhnya
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
Menerima pesertaFase 1Sukarelawan sehat diterima
- George Washington University, Washington D.C.
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Menerima pesertaFase 1Sukarelawan sehat diterima
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Viral Infections in Healthy and Immunocompromised Hosts
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Genetic Studies of Chronic Active Epstein-Barr Disease
Menerima pesertaStudi observasional
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
Menerima pesertaFase 1
- Children's National Hospital, Washington D.C.
- National Institutes of Health (NIH), Bethesda · 7 mi jauhnya
Uji klinis Infeksi Virus di kota lain
- Boston, MA6 studi
- Houston, TX6 studi
- Hialeah, FL5 studi
- Baltimore, MD5 studi
- Atlanta, GA4 studi
- Cincinnati, OH4 studi
- Dallas, TX4 studi
- Columbus, OH4 studi
- Worcester, MA3 studi
- Los Angeles, CA3 studi
- Tampa, FL3 studi
- Miami, FL3 studi
Studi lain di Washington
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil55 studi
- Kanker Payudara46 studi
- Kanker Metastatik43 studi
- Kanker Paru41 studi
- Kanker Prostat38 studi
- Obesitas33 studi
- Kanker Kolorektal29 studi
- Penyakit Kardiovaskular28 studi
- Kanker Kandung Kemih26 studi
- Leukemia Mieloid Akut24 studi
- Kanker Ovarium23 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.